What is it about?

GENETIC EVENTS IN CHRONIC LYMPHOCYTIC LEUKEMIA Aurelian Udristioiu, Molecular Biology, Medicine Faculty, Titu Maiorescu University, Bucharest, Romania, E- mai; : aurelianu2007@yahoo.com ABSTRACT Aim of this study is to present the latest researches in the field of molecular medicine, in terms of Chronic Lymphocytic Leukemia (CLL), emerged from the P53 gene deletion in human lymphoma genome. Method In recent years proved that the best technique in the investigation of malignant lymphocytes is the Fluorescence in situ hybridization (FISH). This method is used as an alternative to chromosomal banding, a conventional application in molecular medicine. Previous results: In the literature it was registered, in previous years, on an international study, conducted on 109 cases of CLL, 79 cases (72.5%) who had more genetic abnormalities: the remaining 30 cases (27.5%) had normal results, using FISH technology. The majority of patients, 67% (53.79) had a single anomaly and the remaining 33% had two or three genetic abnormalities. The chromosomes 14q32 /17p translocations in LLC genome, which appeared similar to some common, had demonstrated abnormalities involving IGH gene, located on chromosome14q32. Discussion Recent, endogenous somatic gene therapy research is a basic of trial clinical and therapeutic trial. The DNA, is used to treat a disease arising as a result of mutations in chromosomal regions. In the past few years, this method has been included in the treatment of CLL, acute lymphocytic leukemia, [ALL], or multiple myeloma [MM]. Conclusion The frequencies of P53 gene mutations and deletion in CLL can be categorized as individual biomarkers in proteomic and genomic profile for this type of leukemia that can be implemented in targeted patient treatment of personalized medicine. Keywords: P-53 Gene, Lymphocytic Leukemia, Apoptosis, Fluorescence in Situ Hybridization

Featured Image

Why is it important?

The studies of genotypic and phenotypic chromosomes aberrations by FISH method allow the identification of differential diagnosis at patients with CCL. The frequencies of gene mutations, deletions or translocations of P53, in CLL, can be classified as biomarkers of individual proteomic and genomic profile for this type of leukemia. Identification of P53 gene deletions and mutations in regions of chromosome 17 in hematological malignancies is important because these mutations have an impact on the clinical management of patients and requires an attitude adjustment therapeutic adequate in a personalized medicine. Personalized treatments will be applied by combining diagnostic tools, knowledge databases and therapeutic drugs.


New cancer therapies Somatic gene therapy has become a research table in clinical trials using a therapeutic DNA, for the treatment of diseases . In recent studies has included the method for the treatment of CLL. In experimental models, disrupting the MDM2–p53 interaction restored p53 function and sensitized tumors to chemotherapy or radiotherapy. For example in hematologic malignancies, such as multiple myeloma, chronic lymphocytic leukemia (CLL), the induction of p53 – using a small MDM2-inhibitor molecule, nutlin-3 – can induce the apoptosis of malignant cells. Nutlins are a group of cis-imidazoline analogs which have a high binding potency and selectivity for MDM2. Nutlin-3 displaces p53 by competing for MDM2 binding. It has also been found that nutlin-3 potently induces apoptosis in cell lines derived from hematologic malignancies and B-cell CLL with frequent translocation 14q32- 17p, with a good therapeutic response.

Professor Aurelian Udristioiu
Hematology and Oncology Specialists LLC

Read the Original

This page is a summary of: Role of P53 gene in oncogenenesis of Chronic Lymphocytic Leukemia, Frontiers in Neurology, January 2016, Frontiers, DOI: 10.3389/conf.fneur.2016.59.00101.
You can read the full text:




The following have contributed to this page